Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Current Assets (2016 - 2025)

Regenxbio has reported Current Assets over the past 12 years, most recently at $281.3 million for Q4 2025.

  • Quarterly results put Current Assets at $281.3 million for Q4 2025, up 1.18% from a year ago — trailing twelve months through Dec 2025 was $281.3 million (up 1.18% YoY), and the annual figure for FY2025 was $281.3 million, up 1.18%.
  • Current Assets for Q4 2025 was $281.3 million at Regenxbio, down from $332.0 million in the prior quarter.
  • Over the last five years, Current Assets for RGNX hit a ceiling of $518.8 million in Q4 2021 and a floor of $278.0 million in Q4 2024.
  • Median Current Assets over the past 5 years was $384.0 million (2023), compared with a mean of $386.6 million.
  • Biggest five-year swings in Current Assets: surged 47.42% in 2021 and later decreased 20.78% in 2025.
  • Regenxbio's Current Assets stood at $518.8 million in 2021, then fell by 19.82% to $416.0 million in 2022, then dropped by 19.47% to $335.0 million in 2023, then fell by 17.01% to $278.0 million in 2024, then grew by 1.18% to $281.3 million in 2025.
  • The last three reported values for Current Assets were $281.3 million (Q4 2025), $332.0 million (Q3 2025), and $373.8 million (Q2 2025) per Business Quant data.